Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR3A | P46098 | 5/20 | 0.58 |
| ▸ | CHRNA7 | P36544 | 11/20 | 0.57 |
| ▸ | HTR3E | A5X5Y0 | 4/20 | 0.57 |
| ▸ | HTR3B | O95264 | 4/20 | 0.57 |
| ▸ | HTR3D | Q70Z44 | 4/20 | 0.57 |
| ▸ | HTR3C | Q8WXA8 | 4/20 | 0.57 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.57 |
| ▸ | TSHR | P16473 | 1/20 | 0.57 |
| ▸ | CHRNB4 | P30926 | 2/20 | 0.55 |
| ▸ | CHRNA3 | P32297 | 2/20 | 0.55 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL280545 | 1.00 | HTR3A (0.58) | HTR3ACHRNA7HTR3EHTR3BHTR3D | |
| SCHEMBL4949371 | 0.82 | CHRNA7 (0.61) | HTR3ACHRNA7HTR3EHTR3BHTR3D | |
| SCHEMBL19996931 | 0.82 | CHRNA7 (0.61) | HTR3ACHRNA7HTR3EHTR3BHTR3D | |
| SCHEMBL4936129 | 0.80 | CHRNA7 (0.61) | HTR3ACHRNA7HTR3EHTR3BHTR3D | |
| SCHEMBL19996959 | 0.80 | CHRNA7 (0.61) | HTR3ACHRNA7HTR3EHTR3BHTR3D | |
| SCHEMBL7281353 | 0.79 | CHRNA7 (0.74) | HTR3ACHRNA7HTR3EHTR3BHTR3D | |
| Hydrochloric Acid SCHEMBL9598227 | 0.77 | CHRNA7 (0.72) | HTR3ACHRNA7HTR3EHTR3BHTR3D | |
| SCHEMBL13881240 | 0.77 | HTR3A (0.63) | HTR3ACHRNA7HTR3EHTR3BHTR3D | |
| SCHEMBL13880728 | 0.77 | HTR3A (0.63) | HTR3ACHRNA7HTR3EHTR3BHTR3D | |
| SCHEMBL13881186 | 0.77 | HTR3A (0.63) | HTR3ACHRNA7HTR3EHTR3BHTR3D |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8252811-B2 | Indazoles, benzothiazoles, and benzoisothiazoles, and preparation and uses thereof | MEMORY PHARMACEUTICALS CORPORATION (US) | 2012-08-28 | — | — | US | disclosed |
| US-20120101094-A1 | INDAZOLES, BENZOTHIAZOLES, AND BENZOISOTHIAZOLES, AND PREPARATION AND USES THEREOF | XIE WENGE (US) | 2012-04-26 | — | — | US | disclosed |
| US-8134003-B2 | Indazoles, benzothiazoles, and benzoisothiazoles, and preparation and uses thereof | MEMORY PHARMACEUTICALS CORPORATION (US) | 2012-03-13 | — | — | US | disclosed |
| US-20110212957-A1 | INDAZOLES, BENZOTHIAZOLES, AND BENZOISOTHIAZOLES, AND PREPARATION AND USES THEREOF | XIE WENGE | 2011-09-01 | — | — | US | disclosed |
| US-7429664-B2 | Indazoles, benzothiazoles, and benzoisothiazoles, and preparation and uses thereof | MEMORY PHARMACEUTICALS CORPORATION (US) | 2008-09-30 | — | — | US | disclosed |
| US-7429664-B2 | Indazoles, benzothiazoles, and benzoisothiazoles, and preparation and uses thereof | MEMORY PHARMACEUTICALS CORPORATION (US) | 2008-09-30 | — | — | US | disclosed |
| US-20080176890-A1 | INDAZOLES, BENZOTHIAZOLES, AND BENZOISOTHIAZOLES, AND PREPARATION AND USES THEREOF | XIE WENGE | 2008-07-24 | — | — | US | disclosed |
| US-20080176890-A1 | INDAZOLES, BENZOTHIAZOLES, AND BENZOISOTHIAZOLES, AND PREPARATION AND USES THEREOF | XIE WENGE | 2008-07-24 | — | — | US | disclosed |
| US-20080154037-A1 | INDAZOLES, BENZOTHIAZOLES, AND BENZOISOTHIAZOLES, AND PREPARATION AND USES THEREOF | XIE WENGE | 2008-06-26 | — | — | US | disclosed |
| US-20080154037-A1 | INDAZOLES, BENZOTHIAZOLES, AND BENZOISOTHIAZOLES, AND PREPARATION AND USES THEREOF | XIE WENGE | 2008-06-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120101094-A1 | INDAZOLES, BENZOTHIAZOLES, AND BENZOISOTHIAZOLES, AND PREPARATION AND USES THEREOF | CHRNA7, CHRNA5, CHRNA3 | HTR3A 152/4885CHRNA7 1/4885HTR3E 224/4885 |
| US-20080154037-A1 | INDAZOLES, BENZOTHIAZOLES, AND BENZOISOTHIAZOLES, AND PREPARATION AND USES THEREOF | CHRNA7, CHRNA5, CHRNA3 | HTR3A 152/4885CHRNA7 1/4885HTR3E 224/4885 |
| US-20110212957-A1 | INDAZOLES, BENZOTHIAZOLES, AND BENZOISOTHIAZOLES, AND PREPARATION AND USES THEREOF | CHRNA7, CHRNA5, CHRNA3 | HTR3A 152/4885CHRNA7 1/4885HTR3E 224/4885 |
| US-20080176890-A1 | INDAZOLES, BENZOTHIAZOLES, AND BENZOISOTHIAZOLES, AND PREPARATION AND USES THEREOF | CHRNA7, CHRNA5, CHRNA3 | HTR3A 152/4885CHRNA7 1/4885HTR3E 224/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.